NEPHROPLUS

NephroPlus (Nephrocare Health Services) – The Recovery Play Current Status: Since its IPO in December 2025 (Issue Price: ₹460), it has been a star performer. It is currently trading near ₹577, having just reported stellar Q3 results (Revenue up 31% YoY). View: Strong Buy on Dips. The Scalp Strategy: It is currently consolidating after a post-earnings rally. It’s a very "clean" mover with less operator noise than Prime Focus. Entry: ₹575–₹580. Target (for the Hit): ₹590 (2% gain). Stop Loss: ₹565. RA Insight: Analysts have a consensus target of ₹615. It’s safer than KPIT because healthcare is currently a "defensive" sector where money is hiding while IT remains volatile.